Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA & PD-1.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Medicxi
Deal Size: $97.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 29, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP Peanut
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Details:
Under the collaboration, Silence is responsible for executing the development program for SLN501 until the end of 1 phase I, after which Mallinckrodt will assume responsibility for clinical development and global commercialization.
Lead Product(s): SLN501
Therapeutic Area: Immunology Product Name: SLN501
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Mallinckrodt Pharmaceuticals
Deal Size: $2,024.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration March 23, 2022
Details:
Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform.
Lead Product(s): QEL-001
Therapeutic Area: Immunology Product Name: QEL-001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $156.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 29, 2021
Details:
The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).
Lead Product(s): Multi-modular Engineered Treg Cell Therapy
Therapeutic Area: Immunology Product Name: QEL-001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.
Lead Product(s): SLN501
Therapeutic Area: Immunology Product Name: SLN501
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Mallinckrodt Pharmaceuticals
Deal Size: $2,020.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration April 28, 2021
